New inhaler targets hidden inflammation in damaged lungs
NCT ID NCT05270525
Summary
This study is testing whether a new inhaled medicine called ensifentrine can reduce harmful inflammation in the lungs of people with COPD. 56 participants with moderate to severe COPD will use the medicine or a placebo inhaler twice daily for 8-week periods, with researchers measuring inflammation markers in their mucus and checking lung function. The goal is to see if this medicine can help control the underlying disease process beyond just relieving symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COPD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35205, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Pittsburgh Medical Center
RECRUITINGPittsburgh, Pennsylvania, 15213, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.